(MENAFN- Media OutReach Newswire)
Proprietary AptegraTM platform reduces five assays to one Results in 66% faster testing time and significantly lower cost for clients compared to traditional methods Only platform that meets all regulatory requirements to establish CHO genetic stability with a single test
SINGAPORE - Media OutReach Newswire - 17 April 2024 - Merck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind. The Aptegra
TM CHO genetic stability assay leverages whole genome sequencing and bioinformatics to significantly accelerate biosafety testing for clients and therefore, their move into commercial production.
"Driving innovation in biosafety testing is essential to bringing new therapies to patients faster," said Benjamin Hein, Head of Life Science Services, Life Science business of Merck. "CHO genetic stability testing has remained relatively unchanged for many years. The Aptegra
TM platform transforms biosafety testing with a digital solution using next-generation sequencing."
A scientist preparing samples in the next-generation sequencing laboratory at Merck's/MilliporeSigma's Rockville, Maryland, USA site. Currently, FDA guidance requires biotech companies to use multiple assays to address genetic stability requirements. This traditional package of assays is costly, time-consuming, and often results in data that need additional interpretation and support. The Aptegra
TM platform addresses these pain points by replacing five different assays and four different technologies with one assay utilizing the next-generation sequencing technology platform. This approach reduces testing time by 66 percent and reduces costs by 43 percent compared to traditional methods. The platform meets all regulatory requirements for genetic stability assurance, including copy number assessment.
Merck has made significant investments over the last five years to expand its biosafety testing capabilities for clients across the globe. The company's global biosafety testing network includes sites in Shanghai, China; Singapore; Stirling and Glasgow, UK; and Rockville, MD, USA.
The Aptegra
TM digital platform adds to a transformative portfolio of digital technologies developed by Merck. In December, Merck launched AIDDISONTM, an AI-powered platform that integrates generative design with predictive synthesis planning, allowing rapid identification of promising candidates and reducing risk of late-stage failures. Additionally, Merck offers a first of its kind Bio4C® Software Suite, which combines data analytics and visualization, automation, and control software for GMP manufacturing.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to to register online, change your selection or discontinue this service.
MENAFN16042024003551001712ID1108103398
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.